Bruce Power, Saugeen Ojibway Nation, Isogen and ITEM are doubling down on production of cancer fighting medial isotopes.
Commercial production of lutetium-177 began last week on a second production line of the Isotope Production System on Bruce Powers Unit 7 which will now double their production capabilities.
This increase will allow Bruce Power and their partners to meet the growing demand for cancer fighting lutetium-177 used to treat cancer patients around the world.
This new line is the final part of a phased approach to expand capacity for Unit 7’s production, a project which started in 2023.